Gynecologic Cancers

‘Breakthrough’ in Recurrent Ovarian Cancer: Niraparib Extends Progression-Free Survival in Platinum-Sensitive Disease

A landmark study showed that the investigational PARP (poly ADP-ribose polymerase) 1/2 inhibitor niraparib, when used as maintenance therapy, significantly improves the outcome of...


Prospective Cutaneous Lymphoma International Prognostic Index Initiative Moves Forward

A collaboration of international experts is tackling the challenges involved in understanding and managing the treatment of cutaneous lymphomas. The Prospective Cutaneous Lymphoma...

Breast Cancer

Equivalent Response Rates With Trastuzumab or Trastuzumab Biosimilar Plus Taxane in HER2-Positive Metastatic Breast Cancer

In part 1 of a phase III equivalence trial reported in JAMA, Rugo et al found that treatment with trastuzumab or a proposed trastuzumab biosimilar in combination with a taxane produced...


More Top Stories


Steven Le Gouill, MD, PhD, on Mantle Cell Lymphoma: Final Results From the LyMa Trial

Cost of Care
Issues in Oncology

As More Biosimilars Move Toward U.S. Market, Questions Remain About Cost Savings and Uptake by Physicians and Patients

The U.S. Food and Drug Administration (FDA) approved its first biosimilar drug, filgrastim-sndz (Zarxio), in 2015, allowing it to compete with the granulocyte colony-stimulating factor filgrastim (Neupogen) to treat neutropenia in chemotherapy patients. So far, filgrastim-sndz is the only...


ASCO Praises Congress for Accelerating the Development and Delivery of Cancer Treatment With 21st Century Cures Act

In a statement released December 7, ASCO President Daniel F. Hayes, MD, FACP, FASCO, said, “ASCO applauds the U.S. Senate for their decisive vote today to pass the 21st Century Cures Act and authorize funding for the Beau Biden Cancer Moonshot and National Institutes of Health Innovation ...


Jonathon Cohen, MD, and Sagar Lonial, MD, on DLBCL: Results of the CALGB/Alliance 50303 Trial

Research Community Forum 2016 Annual Meeting: Using Collective Wisdom to Improve Cancer Research

The ASCO Research Community Forum held its 2016 Annual Meeting from September 25–26, at ASCO headquarters in Alexandria, Virginia. Nearly 100 physician investigators and research staff from all types of research sites across the United States attended the meeting.

Each year, the ASCO Research...

Charles S. Fuchs, MD, MPH, to Lead Yale Cancer Center and Smilow Cancer Hospital

Smilow Cancer Hospital at Yale New Haven and Yale Cancer Center (YCC) have announced that Charles S. Fuchs, MD, MPH, will become the new Director and Physician-in-Chief at Smilow Cancer Hospital at Yale New Haven, effective January 1, 2017.

Dr. Fuchs will be taking the reins of the Smilow Cancer ...

Successful Retreatment With Cisplatin-Based Therapy Reported in Men Relapsing After Adjuvant Carboplatin for Stage I Seminoma

In an analysis reported in the Journal of Clinical Oncology, Fischer et al found that men with clinical stage I seminoma who relapsed after adjuvant carboplatin could be successfully re-treated with cisplatin-based chemotherapy.

Study Details

The analysis included data from 185 patients who...


Laurie H. Sehn, MD, MPH, on Follicular Lymphoma: Choosing the Best Target

Breast Cancer

Chemotherapy May Be Avoidable in Some Women With Early-Stage Breast Cancer Based on Clinical and Genomic Risks

In the phase III MINDACT trial reported in The New England Journal of Medicine, Fatima Cardoso, MD, of Champalimaud Clinical Center–Champalimaud Foundation, Lisbon, and colleagues found that adjuvant chemotherapy may be avoidable in women with early-stage breast cancer who are at high clinical...


No Significant Benefit of Perindopril or Bisoprolol in Reducing Trastuzumab-Associated Cardiac Remodeling in HER2-Positive Breast Cancer

Use of the angiotensin-converting enzyme inhibitor perindopril or the beta-blocker bisoprolol did not reduce the risk of trastuzumab (Herceptin)-related cardiac remodeling in women with HER2-positive early breast cancer, according to a Canadian trial reported by Pituskin et al in the Journal of...

click me